Loading clinical trials...
Loading clinical trials...
IGEV +/- Bortezomib (Velcade) as Induction Before High Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma After First Line Treatment: a Randomized Phase II Trial. On Behalf of Intergruppo Italiano Linfomi
Conditions
Interventions
Ifosfamide, Gemcitabine, Vinorelbine
Bortezomib + IGEV
Locations
1
Italy
Istituto Clinico Humanitas
Rozzano, Milan, Italy
Start Date
February 1, 2008
Primary Completion Date
April 1, 2008
Completion Date
February 1, 2010
Last Updated
September 2, 2010
NCT07209059
NCT02287311
NCT07449832
NCT04998331
NCT02057185
NCT01858922
Lead Sponsor
Istituto Clinico Humanitas
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions